News

Sofinnova closes $815M crossover fund to back late-stage life sciences

What's the deal? Sofinnova Partners has closed its second crossover fund, Sofinnova Crossover II, at €725 million ($815 million), exceeding its original target. The Paris-based life sciences venture firm plans to back around 15 clinical-stage biopharma and medtech companies, primarily in Europe, with selective investments in the US and other markets.

What's the endgame? The fund targets late-stage companies moving toward commercialization and global expansion. It has already backed Hemab Therapeutics, CellCentric, and Neurent Medical.

Who's backing it? Investors include the European Tech Champions Initiative, a fund of funds managed by the European Investment Fund. The strategy is led by partners Joe Anderson, Kinam Hong, Cedric Moreau, Jacques Theurillat, and David Evans.

Why now? "The scale of this fund reflects both the maturity of the European life sciences ecosystem and the rising demand for capital that can help companies to reach global markets," said Antoine Papiernik, chairman and managing partner. Crossover II roughly doubles the firm's first crossover fund, which closed at €445 million in 2021.

What's the track record? Crossover I backed companies including LimFlow, acquired by Inari Medical; Calliditas Therapeutics, acquired by Asahi KaseiDealroom has a profile for this one. Try Dealroom →; Amolyt Pharma, acquired by AstraZeneca; and Abivax, which listed on Nasdaq. Founded in 1972, Sofinnova now manages over €4 billion in assets.

The signal: The close adds to a wave of large fundraises by European healthcare investors. Sofinnova closed its €650 million Capital XI in 2025, while Paris-based Jeito CapitalDealroom has a profile for this one. Try Dealroom → reportedly raised about €1 billion for its second biopharma fund in 2026 — a sign that investors remain willing to back specialist European life sciences platforms.

Read more: finance.yahoo.com

Image credit: Generated with Gemini

More top stories